Abstract 4992
Background
After a cancer diagnosis, exercise (EX) has shown to reduce risk of recurrence/mortality, help in managing cancer treatment side effects and maintain functional abilities. Nevertheless, most of cancer patients are insufficiently active. The purpose of this research is to investigate the EX level, interest and preference in oncological patients.
Methods
A self-administered questionnaire was used to collect demographic, health and EX information. EX level was assessed by leisure score index (LSI), using the validated Godin’s Leisure Time Exercise Questionnaire, while the EX preferences questions were drawn from previous studies. Patients from Medical Oncology Unit of Verona Hospital were asked to anonymously complete the questionnaire. Descriptive statistic was used to calculate frequencies and percentages of responses to survey questions.
Results
With a 57% of response rate, a total of 405 survey were completed and analyzed. Breast (26%) and upper gastrointestinal (42%) were the most frequent diagnosis. Only 10% of patients resulted to be sufficiently active (LSI≥24). A large majority (80%) indicated that they are willing to participate in an EX program designed for cancer patients. Patients reported that they prefer receive EX information by an oncologist (57%) followed by physiotherapist (29%), with a face to face approach (71%). The preferred composition of EX group was with “other cancer patients” (27%). The patients chose outdoors (27%) and a fitness center for adapted physical activity (21%) as favorite places to perform EX. Training in group was preferred (39%), followed by an individual program to perform at home (27%) and an individual program with a personal trainer (25%). The majority preferred a supervised Ex program (57%). The favorite EX frequencies were two times/week (37%) and three times/week (30%), whereas “mild” intensity was chosen by 44% of patients followed by “moderate” (36%).
Conclusions
Despite the demonstrated benefits of EX in oncological patients, we found 90% of them insufficiently active, but 80% willing to start an EX program. According to these data, we designed a prospective clinical trial including dedicated EX programs based on patient’s preferences, currently recruiting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Verona.
Funding
Has not received any funding.
Disclosure
E. Bria: Honoraria (self): MSD, AstraZeneca, Celgene, Pfizer, Helsinn, Eli-Lilly, BMS, Novartis, and Roche; Research grant / Funding (self): AIRC. S. Pilotto: Honoraria (self): AstraZeneca, BMS, Roche, MSD, Boeringher Ingelheim; Research grant / Funding (self): AIRC; Travel / Accommodation / Expenses: BMS, Roche, AstraZeneca, Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
5344 - Global trends in population-based survival for 303,169 adults diagnosed with glioblastoma in 44 countries during 2000-2014 (CONCORD-3)
Presenter: Fabio Girardi
Session: Poster Display session 1
Resources:
Abstract
3088 - Spanish Survey of treatment recommendations for elderley patients with glioblastoma
Presenter: María Ángeles Vaz Salgado
Session: Poster Display session 1
Resources:
Abstract
3484 - Updated analysis of the National Registry of Nervous System Tumors in Spain (RETSINE). RETSINE: National Registry of Nervous System Tumors of the Spanish Research Group in Neuro-oncology (GEINO) and Spanish Infrequent and Orphan Tumors Group (GETHI)
Presenter: Isaac Ceballos Lenza
Session: Poster Display session 1
Resources:
Abstract
4737 - Development and validation of novel nomograms predicting survival of malignant ependymoma patients: A population-based study
Presenter: Alzhraa Abbas
Session: Poster Display session 1
Resources:
Abstract
4740 - Characteristics, incidence, and survival of primary cerebral lymphoma: A population based study
Presenter: Sherief Ghozy
Session: Poster Display session 1
Resources:
Abstract
5362 - Trends in Incidence and Survival Analyses of Adult-onset Medulloblastoma
Presenter: Feifei Lin
Session: Poster Display session 1
Resources:
Abstract
3868 - Meta of classical chemotherapy compared with high-dose chemotherapy combined with autologous stem cell transplantation in newly diagnosed medulloblastoma patients after radiotherapy
Presenter: Mengting Zhang
Session: Poster Display session 1
Resources:
Abstract
4446 - Effect of cumulative dose of maintenance temozolomide on overall survival in patients with high grade glia tumors: a single institution analysis
Presenter: Marta Nerone
Session: Poster Display session 1
Resources:
Abstract
5119 - Markers of systemic inflammation correlate with survival prognosis in patients with newly diagnosed brain metastases
Presenter: Angelika Starzer
Session: Poster Display session 1
Resources:
Abstract
3882 - Venous Thromboembolism and Intracranial Hemorrhage in Patients with High-grade Glioma
Presenter: Clara Borges
Session: Poster Display session 1
Resources:
Abstract